phentermine has been researched along with qsymia in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (94.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Mercer, SL | 1 |
| Bello, NT; Campbell, SC | 1 |
| Howland, RH | 2 |
| Bouchie, A | 1 |
| Kallikazaros, I; Kallistratos, MS; Katsi, V; Makris, T; Manolis, AJ; Marketou, M; Tousoulis, D; Vardas, P | 1 |
| Murfin, M | 1 |
| Blomain, ES; Kim, GW; Lin, JE; Waldman, SA | 1 |
| Gadde, KM; Xiong, GL | 1 |
| Azebu, LM | 1 |
| Nakazato, M; Ueno, H | 1 |
| Finkelstein, EA; Karnawat, S; Kruger, E | 1 |
| Diamond, F | 1 |
| Mehr, SR; Zimmerman, MP | 1 |
| Curry, SA | 1 |
| Adler, S; Dalai, SS; Najarian, T; Safer, DL | 1 |
| Friedman, Y | 1 |
5 review(s) available for phentermine and qsymia
| Article | Year |
|---|---|
Phentermine and topiramate extended-release for the obesity: new kids on the block.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Obesity; Patents as Topic; Phentermine; Topiramate; Treatment Outcome; Weight Loss | 2013 |
Antiobesity pharmacotherapy: new drugs and emerging targets.
Topics: Animals; Anti-Obesity Agents; Benzazepines; Drug Combinations; Drug Delivery Systems; Drug Discovery; Fructose; Humans; Obesity; Phentermine | 2014 |
Combination phentermine/topiramate for obesity treatment in primary care: a review.
Topics: Anti-Obesity Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Fructose; Humans; Obesity; Phentermine; Primary Health Care; Topiramate; Treatment Outcome; United States; Weight Loss | 2014 |
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate | 2014 |
Three drugs facing key patent expirations and potential generic entry from June 2020 to July 2020.
Topics: Dimethyl Fumarate; Drug Combinations; Drug Industry; Drugs, Generic; Fructose; Guanine; Humans; Patents as Topic; Phentermine | 2020 |
1 trial(s) available for phentermine and qsymia
| Article | Year |
|---|---|
Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
Topics: Adolescent; Adult; Appetite Depressants; Binge-Eating Disorder; Bulimia Nervosa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Fructose; Humans; Male; Middle Aged; Phentermine; Prospective Studies; Research Design; Young Adult | 2018 |
12 other study(ies) available for phentermine and qsymia
| Article | Year |
|---|---|
ACS chemical neuroscience molecule spotlight on Qnexa.
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials, Phase III as Topic; Comorbidity; Double-Blind Method; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Overweight; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Treatment Outcome; United States; United States Food and Drug Administration; Weight Loss | 2011 |
Two anti-obesity hopefuls and their safety.
Topics: Adult; Anti-Obesity Agents; Benzazepines; Dose-Response Relationship, Drug; Drug Combinations; Drugs, Investigational; Female; Fructose; Heart Valve Diseases; Humans; Male; Obesity; Phentermine; Pregnancy; Tachycardia; Teratogens; Topiramate; Weight Loss | 2012 |
Off-label medication use.
Topics: Anti-Obesity Agents; Anticonvulsants; Bipolar Disorder; Child; Delayed-Action Preparations; Drug Approval; Drug Combinations; Evidence-Based Medicine; Fructose; Humans; Informed Consent; Off-Label Use; Parental Consent; Phentermine; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Loss | 2012 |
Regulatory fog lifts on obesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Drug Combinations; Fructose; Legislation, Drug; Phentermine; United States; United States Food and Drug Administration | 2012 |
2 new drugs for weight loss.
Topics: Anti-Obesity Agents; Benzazepines; Drug Combinations; Drug Interactions; Fructose; Humans; Obesity; Overweight; Phentermine; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Weight Loss | 2012 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic | 2013 |
New medications for weight loss.
Topics: Appetite Depressants; Benzazepines; Drug Combinations; Fructose; Humans; Obesity; Overweight; Phentermine; Weight Loss | 2012 |
The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
Topics: Anti-Obesity Agents; Benzazepines; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Risk Assessment; United States; United States Food and Drug Administration | 2014 |
Cost-Effectiveness Analysis of Qsymia for Weight Loss.
Topics: Anti-Obesity Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Fructose; Humans; Obesity; Phentermine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Weight Loss | 2015 |
Aetna includes medications in weight-loss strategies.
Topics: Anti-Obesity Agents; Benzazepines; Drug Combinations; Fructose; Humans; Managed Care Programs; Organizational Case Studies; Phentermine; United States; Weight Reduction Programs | 2014 |
Nonincretin drugs in later-stage development.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs, Investigational; Fructose; Humans; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration | 2014 |
Obesity Epidemic: Pharmaceutical Weight Loss.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss | 2017 |